

**Strengthening Risk Evaluation and Mitigation Strategies (REMS) Through Systematic Analysis,
Standardized Design, and Evidence-Based Assessment**

The Brookings Institution • Washington, DC
Wednesday, September 25, 2013

Participant List

Julie Aker

President and CEO, Concentrics Research

James Bagian

Director, Center for Healthcare Engineering
Patient Safety, University of Michigan

Ben Berman

Senior Research Associate, San Jose State
University /NASA Ames Research Center

Raymond Coghlan

Director, REMS, U.S. Medical, Bristol-Myers
Squibb Company

Richard Currey

Science Policy Analyst, Office of the Center
Director, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration

Gregory Daniel

Managing Director and Fellow, Engelberg Center
for Health Care Reform, The Brookings Institution

Tom Davis

Vice President, Pharmacy Professional Services,
CVS/Caremark Corporation

Joe DeRosier

Program Manager, Center for Healthcare
Engineering and Patient Safety, University of
Michigan

Rachael DiSantostefano

Director, Worldwide Epidemiology,
GlaxoSmithKline

Jeff Fetterman

President, ParagonRx

Nancy Globus

Director of Operations, Med-ERRS

Ayse Gurses

Associate Professor, Johns Hopkins University
School of Medicine

Florence Houn

Vice President, Regulatory Policy & Strategy,
Celgene Corporation

Diana Hughes

Vice President, Primary Care Business Unit
Safety Lead, Pfizer

Michael Kalsher

Associate Professor, Rensselaer Polytechnic
Institute

Mwango Kashoki

Associate Director for Safety, Office of New
Drugs, Center for Drug Evaluation and Research,
U.S. Food and Drug Administration

Larry Kocot

Visiting Fellow, The Brookings Institution

Adam Kroetsch

Operations Research Analyst, Office of Program
and Strategic Analysis, Office of Strategic
Programs, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration

Claudia Manzo

Director, Division of Risk Management, Office of
Medication Error Prevention and Risk
Management, Office of Surveillance and
Epidemiology, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration

Mark McClellan

Senior Fellow and Director, Health Care
Innovation and Value Initiative, The Brookings
Institution

Thomas E. Menighan

Executive Vice President and Chief Executive
Officer, American Pharmacists Association

Megan Moncur

Regulatory Health Policy Analyst, Division of Risk Management, Office of Medication Error Prevention and Risk Management, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Elaine Morrato

Associate Professor, University of Colorado, Anschutz Medical Campus

M. Elisabeth Paté-Cornell

Professor and Past Chair, Department of Management Science and Engineering; and The Burt and Deedee McMurtry Professor in the School of Engineering, Stanford University

Larry Risen

President and CEO, BioTrak Research

Nancy Santanello

Vice President, Epidemiology, Merck Research Laboratories

Paul Seligman

Executive Director, Global Regulatory Policy, Amgen

Gary Slatko

Director, Office of Medication Error Prevention and Risk Management, Office of Surveillance and Epidemiology, U.S. Food and Drug Administration

Meredith Smith

Senior Scientific Director, Risk Management, AbbVie

Mary Ellen Turner

Consultant, Mary Ellen Turner Consulting

Carla Van Bennekom

Epidemiologist, Slone Epidemiology Center at Boston University

Mary Willy

Associate Director, Division of Risk Management, Office of Medication Error Prevention and Risk Management, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Joel Wu

Research Associate, Engelberg Center for Health Care Reform, The Brookings Institution